Blue­bird shares tank af­ter FDA puts an­oth­er hold on its long de­layed sick­le cell gene ther­a­py

Blue­bird bio has been hit with an­oth­er hold on one of its gene ther­a­py pro­grams.

The com­pa­ny an­nounced Mon­day that the FDA had placed a par­tial hold on its sick­le cell gene ther­a­py tri­als for chil­dren un­der the age 18, af­ter one ado­les­cent pa­tient was di­ag­nosed with per­sis­tent ane­mia.

The biotech’s sci­en­tists are still try­ing to de­ter­mine the cause of the pa­tient’s ane­mia, but the com­pa­ny em­pha­sized the in­di­vid­ual is in oth­er­wise good health and has not suf­fered any of the pain crises that are a hall­mark of the dis­ease. The ane­mia, they not­ed, is not se­vere enough to re­quire trans­fu­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.